Medial EarlySign and Lucem Health Unveil 3-Part Blog Series on Early Detection of

Lung Cancer with AI

TEL AVIV, Israel – February 04, 2025— Medial EarlySign, a leader in AI-driven solutions for early disease detection, is proud to announce the release of a comprehensive 3-part blog series focused on the critical role of early detection in the fight against lung cancer. In partnership with Lucem Health, Medial EarlySign convened a world-class roundtable of clinicians, data scientists, and researchers to explore the intersection of artificial intelligence (AI) and healthcare.

The roundtable discussion, titled "Foundations of AI for Early Detection of Lung Cancer," brought together diverse experts to examine the essential components required to build effective AI models for early lung cancer detection. From data science to real-world clinical application, the series provides a thorough examination of the transformative potential AI holds for improving outcomes in one of the most challenging areas of healthcare.

A Deep Dive Into Early Detection

The first two installments of the blog series offer insights into:

- The Data Behind AI Models: How data is collected, curated, and used to train AI for early detection.

- Validation in the Real World: The challenges and strategies for ensuring AI tools perform effectively in clinical practice.

- Clinical and Financial Impact: How AI augments standard screening protocols to improve outcomes while driving cost efficiencies.

The final installment of the series takes a closer look at equity, ethics, and the future of AI in clinical care, addressing pressing topics such as:

- Equity and Fairness: Ensuring AI-driven solutions serve all patient populations equitably.

- AI and Physicians: Dispelling myths about AI replacing doctors, focusing instead on the collaborative efficiencies AI can create.

- Real-World Efficiencies: Exploring how AI-driven screening can streamline workflows and improve patient outcomes.

Sean Cassidy, CEO of Lucem Health, emphasized the critical need to address low lung cancer screening rates in the U.S., stating, "Lung cancer remains the leading cause of cancer deaths, yet screening rates are far too low—less than 10% of eligible patients receive the recommended screenings. AI has the potential to change that by identifying high-risk individuals earlier and ensuring that more patients can benefit from life-saving interventions."

"This blog series reflects our commitment to advancing the conversation around AI's role in healthcare and supporting early detection efforts," commented Ori Geva, CEO of Medial EarlySign. "Highlighting the life-saving potential of proven AI tools, validated AI models have the power to identify those at the highest risk, enabling faster and more personalized treatment when it matters most. Early detection through AI isn't just about improving outcomes; it's about saving lives by ensuring that patients receive the right care at the right time."

Access the Full Blog Series

Medial EarlySign and Lucem Health invite clinicians, researchers, and healthcare leaders to explore this timely and critical series, which highlights how AI can help combat one of the world's most significant health challenges. The 3-part series is available now on the Lucem Health, Visit https://lucemhealth.com/blog/foundations-ai-early-detection-lung-cancer-pt-1/ to read the expert insights and join the conversation about the future of AI in early lung cancer detection.

About Medial EarlySign
Medial EarlySign is at the forefront of harnessing AI and machine learning to transform healthcare by identifying high-risk patients for significant medical conditions, enabling earlier intervention and better outcomes. For more information, visit www.earlysign.com.

About Lucem Health
Lucem Health enables healthcare organizations to harness the power of AI to improve patient outcomes. Its solutions simplify the integration of advanced analytics into clinical workflows, driving meaningful change in healthcare delivery. Learn more at www.lucemhealth.com.

EarlySign Media Contact:

Darrell Atkin
darrella@earlysign.com
+1.760.390.6036